USPTO grants patent titled 'method of therapeutic administration of DHE' to MAP Pharma

The United States Patent and Trademark Office (USPTO) issued to the MAP Pharmaceuticals' US Patent No. 8,119,639, titled "Method of Therapeutic Administration of DHE to Enable Rapid Relief of Migraine while Minimizing Side Effect Profile."  

Scope, Implications of Section 3(d) Of the Indian Patents Act, 1970 (As Amended)

Under Indian patent law, there are certain inventions which are deemed specifically not patentable.

These are identified in Section 3, and the sub-clause of that section which is relevant with respect to the infamous Novartis case pending before the Chennai High Court and now also IPAB [Intellectual Property Appellate Board] is sub-clause (d) of Section 3.

Natco Pharma files India's first compulsory license plea

Natco Pharma has applied for the country's first compulsory licence to sell a generic version of Bayer's patented medicine, a development whose outcome is expected to determine how global drug makers price their costly drugs in India.

In compulsory licensing, the government allows a generic firm to produce a patented product without the consent of the patent owner. It is one of the flexibilities on patent protection included in the WTO's agreement on intellectual property -TRIPS (trade-related aspects of intellectual property rights) Agreement.

Facts: Indian Pharma Import

S.NO	COUNTRIES	APR 2004- MAR 2005 (RS. CRORES)	APRIL 2005 – MAR 2006 (RS.  CRORES)
1	China P Rp	908.57	1563.53
2	Switzerland	375.44	547.35
3	U S A	298.11	425.32
4	Germany	188.82	276.33
5	Denmark	107.48	174.48

10 largest U.S. patent losses

In the drug business, exclusivity is everything. Once a branded drug gets generic competition, pricing power fades and sales slowly drain away, leaving drugmakers dependent on the next new thing. It's all very reasonable in theory, but when the drugs losing patent protection are the biggest in the business--and they're all falling off patent around the same time--even the most rational companies can get a bit panicky.

Welcome to the patent cliff, the most influential feature of today's pharma landscape. Here, so many drugs are falling off patent that the path forward has twisted, and the entire industry is looking to find its way. Some companies, such as Pfizer and Merck, have merged with major rivals. Others have snapped up acquisitions in ancillary businesses, such as generics and over-the-counter medicines, and expanded into countries they previously ignored. Still others have forged ahead, betting that they'd manage to develop enough new products to make up the difference.

WTO

For Presentation on World Trade Organization

Click Here